Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 May;40(5):e15058.
doi: 10.1111/dme.15058. Epub 2023 Feb 7.

Interest in hybrid closed loop is high across the socioeconomic spectrum despite current inequalities in provision in a large UK diabetes centre

Anna R Dover  1 , Stuart A Ritchie  1 , Rohana J Wright  1 , Emily M McMurray  1 , Mark W J Strachan  1 , Roland H Stimson  1 , Shareen Forbes  1 , Fraser W Gibb  1
Affiliations

Interest in hybrid closed loop is high across the socioeconomic spectrum despite current inequalities in provision in a large UK diabetes centre

Anna R Dover et al. Diabet Med. 2023 May.
No abstract available

PubMed Disclaimer

References

REFERENCES

    1. Leelarathna L, Choudhary P, Wilmot EG, et al. Hybrid closed-loop therapy: where are we in 2021? Diabetes Obes Metab. 2021;23(3):655-660. doi:10.1111/dom.14273
    1. Choudhary P, Kolassa R, Keuthage W, et al. Advanced hybrid closed loop therapy versus conventional treatment in adults with type 1 diabetes (ADAPT): a randomised controlled study. Lancet Diabetes Endocrinol. 2022;10(10):720-731. doi:10.1016/S2213-8587(22)00212-1
    1. Brown SA, Kovatchev BP, Raghinaru D, et al. Six-month randomized, multicenter trial of closed-loop control in type 1 diabetes. N Engl J Med. 2019;381(18):1707-1717. doi:10.1056/NEJMoa1907863
    1. Dover AR, Strachan MWJ, McKnight JA, et al. Socioeconomic deprivation, technology use, C-peptide, smoking and other predictors of glycaemic control in adults with type 1 diabetes. Diabet Med. 2021;38(3):e14445. doi:10.1111/dme.14445
    1. Bionic Pancreas Research Group. Multicenter, randomized trial of a bionic pancreas in type 1 diabetes. N Engl J Med. 2022;387(13):1161-1172. doi:10.1056/NEJMoa2205225

Substances

LinkOut - more resources